The Qingdao Port Health Study
1 other identifier
observational
25,000
0 countries
N/A
Brief Summary
China, efforts are underway to respond to an unprecedented epidemiologic transition, with soaring rates of cardiovascular disease (CVD), including heart disease and stroke. Yet there may be limitations in translating observations and findings derived from Anglo-based population studies. As such, there is a critical need for population-based studies that provide insight into the risk factors, incidence, and outcomes of CVD in China. The Qingdao Port Health Study is a population-based prospective cohort study of employees of the Qingdao Port Group, China, designed to investigate the burden of CVD and risk factors (e.g., sociodemographic, biological, environmental and clinical factors) associated with disease onset and outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2013
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2013
CompletedFirst Submitted
Initial submission to the registry
December 20, 2014
CompletedFirst Posted
Study publicly available on registry
January 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2016
CompletedAugust 11, 2016
January 1, 2016
2.8 years
December 20, 2014
August 10, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
all cause mortality
The number of all cause death will be collected. The effects of modified risk factors on all cause mortality will be assessed.
3 year
Secondary Outcomes (3)
Heart diseases (defined as myocardial infarction, agina requiring hospitalization and acute/chronic heart failure)
3 year
stroke (defined as ischemic stroke and hemorraghic stroke)
3 year
revascularization (defined as percutaneous coronary intervention, coronary artery bypass grafting and percutaneous transluminal coronary angioplasty)
3 year
Other Outcomes (4)
chronic obstructive pulmonary disease
3 year
chronic renal insufficiency
3 year
chronic liver diseases (defined as cirrhosis and hepatic failure)
3 year
- +1 more other outcomes
Eligibility Criteria
Employees and retirees in Qingdao Port Group, Shandong province, China
You may qualify if:
- All employees and retirees in Qingdao Port Group
- Aged over 18 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Spatz ES, Jiang X, Lu J, Masoudi FA, Spertus JA, Wang Y, Li X, Downing NS, Nasir K, Du X, Li J, Krumholz HM, Liu X, Jiang L. Qingdao Port Cardiovascular Health Study: a prospective cohort study. BMJ Open. 2015 Dec 9;5(12):e008403. doi: 10.1136/bmjopen-2015-008403.
PMID: 26656011DERIVED
Biospecimen
In 2013, whole blood samples were collected for future genetic studies. And saliva and urine samples were also collected for future analysis.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lixin Jiang, MD, PhD
Chinese Academy of Medical Sciences, Fuwai Hospital
- PRINCIPAL INVESTIGATOR
Xiancheng Liu, MD, PhD
Qingdao Fuwai hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2014
First Posted
January 1, 2015
Study Start
March 1, 2013
Primary Completion
January 1, 2016
Study Completion
January 1, 2016
Last Updated
August 11, 2016
Record last verified: 2016-01